Nuevos esquemas terapéuticos en el manejo de la psoriasis

Autores/as

  • Juan S. Serna-Trejos Universidad Libre, Cali, Colombia
  • Stefanya G. Bermúdez-Moyano Universidad Santiago de Cali, Cali, Colombia
  • Juan F. Rivas Fundación universitaria San Martin, Cali, Colombia
  • John Edison Ortiz - Sabogal Fundación Universitaria Juan N. Corpas, Bogotá, Colombia

DOI:

https://doi.org/10.35839/repis.7.3.1829

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94. doi:10.1016/S0140-6736(14)61909-7

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatology Venereol. 2017;31(2):205–12. doi:10.1111/jdv.13854

Kawada A, Tezuka T, Nakamizo Y, Kimura H, Nakagawa H, Ohkido M, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31(1):59–64. doi:10.1016/S0923-1811(02)00142-1

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. doi:10.1016/j.jaad.2018.11.057

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci . 2019;20(6):1–28. doi:10.3390/ijms20061475

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, et al. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatology Venereol. 2019;33(3):546–52. doi:10.1111/jdv.15258

Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):1–11. doi:10.1186/s13075-019-1882-2

Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–58. doi:10.1111/bjd.18851

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-286.e10. doi:10.1016/j.jaad.2018.03.037

Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–76. doi:10.1111/bjd.14403

Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018;379(14):1313–21. doi:10.1056/nejmoa1806382

Robbins K, Bissonnette R, Maeda-Chubachi T, Ye L, Peppers J, Gallagher K, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–21. doi:10.1016/j.jaad.2018.10.037

Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, et al. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020;383(3):229–39. doi:10.1056/nejmoa2000073

Descargas

Publicado

2023-09-30

Cómo citar

1.
Serna-Trejos JS, Bermúdez-Moyano SG, Rivas JF, Ortiz-Sabogal JE. Nuevos esquemas terapéuticos en el manejo de la psoriasis. Rev Peru Investig Salud [Internet]. 30 de septiembre de 2023 [citado 21 de julio de 2024];7(3):159-61. Disponible en: https://revistas.unheval.edu.pe/index.php/repis/article/view/1829

Número

Sección

Cartas al Editor

Artículos más leídos del mismo autor/a

1 2 > >>